Loading GERN detail
Loading ticker data...
Loading GERN detail
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.
It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
The company was incorporated in 1990 and is headquartered in Foster City, California.
Chart data unavailable
FOSTER CITY, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 11:00 a.m. ET.
Geron Corporation (NASDAQ: GERN - Get Free Report)'s share price passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $1.38 and traded as high as $1.43. Geron shares last traded at $1.41, with a volume of 16,679,509 shares. Analyst Ratings Changes Several brokerages recently issued reports
Patricia S. Andrews and Constantine Chinoporos are proven industry veterans with decades of experience leading and advising biopharmaceutical companies Patricia S. Andrews and Constantine Chinoporos are proven industry veterans with decades of experience leading and advising biopharmaceutical companies
Shares of Geron Corporation (NASDAQ: GERN - Get Free Report) have been assigned an average rating of "Hold" from the seven analysts that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and two have given a buy recommendation to the company.
Geron Corporation's Q4 '25 net product revenues of $48M are similar to those seen in Q4 '24 ($47.5M). Despite fairly flat quarterly revenues, GERN maintains 2026 net product revenue guidance of $220M-$240M, implying 25% growth. Key catalysts include a potential IMpactMF interim readout in H2 '26 and readouts from investigator-sponsored trials and potential real-world data that could encourage use of Rytelo.
FOSTER CITY, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective March 17, 2026, it granted stock options to purchase an aggregate of 956,250 shares of common stock to six newly hired employees as an inducement material to such employees' acceptance of employment with Geron.
Almitas Capital LLC bought a new position in Geron Corporation (NASDAQ: GERN) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 946,323 shares of the biopharmaceutical company's stock, valued at approximately $1,296,000. Almitas Capital LLC owned about 0.15% of Geron at the
Geron Corporation (GERN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Current revenue trends of Geron suggest RYTELO is primarily finding its niche in the later-line "salvage" setting, which may continue to moderate near-term growth expectations. Geron's recent strategic restructuring and workforce reductions reflect a pivot toward financial discipline as the company navigates current uptake patterns and persistent net losses. Intensifying gross-to-net pressures and complex European pricing negotiations suggest a more cautious outlook for RYTELO's global commercial expansion.
Geron (GERN) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.04 per share a year ago.
Geron Corporation (GERN) Q4 2025 Earnings Call Transcript
Achieved $48 million and $184 million in RYTELO® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within the previous guidance range Reiterated 2026 RYTELO net product revenue and total operating expenses expected in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Ended 2025 with cash, cash equivalents, restricted cash and marketable securities of roughly $401 million Company to host conference call and webcast today, February 25, at 8:00 a.m. ET FOSTER CITY, Calif.
FOSTER CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following investor conferences:
Geron Corporation (NASDAQ: GERN - Get Free Report)'s share price dropped 6% on Friday. The stock traded as low as $1.82 and last traded at $1.8050. Approximately 1,252,326 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 13,063,093 shares. The stock had previously closed at $1.92. Analysts Set
FOSTER CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective February 17, 2026, it granted stock options to purchase an aggregate of 742,500 shares of common stock to one newly hired employee as an inducement material to such employee's acceptance of employment with Geron.
